![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1727077
¼¼°èÀÇ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀå - ÀλçÀÌÆ®, °æÀï ±¸µµ, ½ÃÀå ¿¹Ãø(2032³â)Artificial Intelligence (AI) in Remote Patient Monitoring - Market Insights, Competitive Landscape, and Market Forecast - 2032 |
¼¼°èÀÇ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀåÀº Á¦Ç° À¯Çüº°(µð¹ÙÀ̽º, ¼ÒÇÁÆ®¿þ¾î, ¼ºñ½º), ¿ëµµº°(¾Ï, ½ÉÇ÷°ü Áúȯ, »ýȰ ½À°üº´, ±âŸ), ÃÖÁ¾ »ç¿ëÀÚº°(º´¿ø ¹× Áø·á¼Ò, Áø´Ü¼¾ÅÍ, ÀçÅÃÀÇ·áȯ°æ), Áö¿ªº°(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ±âŸ Áö¿ª)À¸·Î ºÐ·ùµÇ¾î ¸¸¼ºÁúȯ À¯º´·ü »ó½Â°ú ¼¼°è Á¦Ç°°³¹ß Ȱµ¿ÀÇ È°¼ºÈ·Î 2032³â±îÁö ´ëÆøÀûÀÎ CAGR ¿¹ÃøÀ¸·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 19¾ï 2,651¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. 2032³â¿¡´Â 131¾ï 2,680¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. »ç·Ê ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó °·ÂÇÑ ¼ºÀåÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ ¼ºÀåÀº Á¦Ç° °³¹ß ÀÌ´Ï¼ÅÆ¼ºêÀÇ ±ÞÁõ, µðÁöÅÐ °Ç° ÀÎÇÁ¶ó¿¡ ´ëÇÑ ¼¼°è ÅõÀÚ Áõ°¡ ¹× »çÀü Ȱ¹ßÇÑ µ¥ÀÌÅÍ ±â¹Ý °Ç° °ü¸®¿¡ ÁßÁ¡À» µÓ´Ï´Ù. 2025³âºÎÅÍ 2032³â±îÀÇ ¿¹Ãø ±â°£ µ¿¾È AI¸¦ Ȱ¿ëÇÑ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM) ½ÃÀåÀÇ ´ëÆøÀûÀÎ È®´ë°¡ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀå ¿ªÇÐ:
±¹Á¦¾Ï ¿¬±¸±â°ü(IARC)ÀÌ 2024³â¿¡ Á¦°øÇÑ µ¥ÀÌÅÍ¿¡ ÀÇÇϸé, 2022³â¿¡´Â ¼¼°è¿¡¼ 2,000¸¸¸íÀÇ ½Å±Ô ¾Ï Áõ·Ê°¡ º¸°íµÇ¾ú´Ù°í ±âÀçµÇ¾î ÀÖ½À´Ï´Ù. º¸°íµÈ ¾Ï Áõ·Ê Áß, Æó¾ÏÀº ¼¼°è¿¡¼ 250¸¸ Áõ·Ê¸¦ Â÷ÁöÇØ, °¡Àå ÀϹÝÀûÀÎ ¾ÏÀÌ µÇ°í ÀÖ½À´Ï´Ù. À¯¹æ¾ÏÀº 230¸¸°Ç, ´ëÀå¾ÏÀº 190¸¸°Ç, À§¾ÏÀº 97¸¸°ÇÀ̾ú½À´Ï´Ù.
Global Cancer Observatory(2024)´Â ¼¼°èÀÇ ½Å±Ô¾Ï ȯÀÚ¼ö´Â 2022³â 2,000¸¸¸í¿¡¼ 2030³â¿¡´Â 2,410¸¸¸í¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾Æ´Â 982¸¸ 6,539¸í, À¯·´Àº 447¸¸ 1,422¸í, ¶óƾ¾Æ¸Þ¸®Ä« Ä«¸®ºêÇØ ±¹°¡(LAC)´Â 155¸¸ 1,060¸í, ¾ÆÇÁ¸®Ä«´Â 118¸¸ 5,216¸íÀ̾ú½À´Ï´Ù.
¼¼°èÀÇ ¾Ï ÀÌȯÀ² Áõ°¡´Â Áö¼ÓÀûÀÌ°í °³º°ÈµÈ Äɾ °¡´ÉÇÏ°Ô ÇÏ´Â AI¸¦ žÀçÇÑ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼ö¿ä¸¦ °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù.
±¹Á¦ ´ç´¢º´ ¿¬ÇÕ(International Diabetes FederationÀÇ µ¥ÀÌÅÍ(2022³â)¿¡ µû¸£¸é, 20-79¼¼ÀÇ ¼ºÀÎ 5¾ï 3,700¸¸¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, ÀÌ´Â ¾à 10¸í¿¡ 1¸í¿¡ »ó´çÇÕ´Ï´Ù. ÁÖ¸ñÇØ¾ßÇÒ °ÍÀº ¼ºÀÎÀÇ ´ç´¢º´ ȯÀÚÀÇ 75% ÀÌ»óÀÌ Àú¼Òµæ ¹× Áß¼Òµæ ±¹°¡¿¡ °ÅÁÖÇϰí ÀÖ´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, 5¾ï 4,100¸¸¸íÀÇ ¼ºÀÎÀÌ ³»´ç´É ÀÌ»ó(IGT)À» °¡Áö°í ÀÖ¾î, 2Çü ´ç´¢º´ÀÇ °³¹ß ¸®½ºÅ©°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
µû¶ó¼, ´ç´¢º´°ú ³»´ç´É ÀÌ»óÀÇ Áõ·Ê°¡ Áõ°¡Çϰí ÀÖ¾î È¿°úÀûÀÎ Áúº´ °ü¸®¿¡´Â Áö¼ÓÀûÀÎ ÃßÀû°ú Á¶±â °³ÀÔÀÌ ºÒ°¡°áÇϱ⠶§¹®¿¡ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ¿¡ ÀÖ¾î¼ AI ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷ÀÇ Áö¼ÓÀûÀÎ Á¦Ç° °³Ã´ÀÌ AI¸¦ Ȱ¿ëÇÑ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM) ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Ä¡°ú ¹× ±³Á¤ Ä¡·á, ±¸°ÀÇ °Ç° »óÅÂ, ÀüüÀûÀÎ Ä¡·á ÁøÇà »óȲÀ» ¿ø°ÝÀ¸·Î ÃßÀûÇÏ´Â °ÍÀ¸·Î, ÇコÄɾî Àü¹®°¡¸¦ ¼Æ÷Æ®Çϵµ·Ï Ưº°È÷ ¼³°èµÇ°í ÀÖ½À´Ï´Ù.
ÇÏÁö¸¸ ¾Ï, ½ÉÇ÷°üÁúȯ, »ýȰ½À°üº´ µîÀÇ ¸¸¼ºÁúȯÀÌ ¸¹ÀÌ º¸À̱⠶§¹®¿¡ Á¦Ç°°³¹ß ÀÌ´Ï¼ÅÆ¼ºêÀÇ Áö¼ÓÀûÀÎ ±ÞÁõ, µðÁöÅÐ Çコ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ¼¼°è ÅõÀÚ Áõ°¡, ¾ÕÀ¸·Î ¿¹ÃøÇÑ µ¥ÀÌÅÍ ÁÖµµÀÇ ÇコÄɾî Á߽ð¡ ³ô¾ÆÁü¿¡ µû¶ó 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ Áß Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀåÀº ¾öû³ ¼ºÀå °¡´É¼º¿¡µµ ºÒ±¸ÇÏ°í ¸î °¡Áö ÁÖ¿ä °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù.
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀå ºÎ¹® ºÐ¼® :
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ¿¡ ÀÖ¾î¼ AI ½ÃÀå : Á¦Ç° À¯Çü(µð¹ÙÀ̽º, ¼ÒÇÁÆ®¿þ¾î, ¼ºñ½º), ¿ëµµ(¾Ï, ½ÉÇ÷°ü Áúȯ, »ýȰ ½À°üº´, ±âŸ), ÃÖÁ¾ »ç¿ëÀÚ(º´¿ø ¹× Áø·á¼Ò, Áø´Ü¼¾ÅÍ, ÀçÅÃÄ¡·á), Áö¿ª(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ±âŸ Áö¿ª)º°
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀåÀÇ Á¦Ç° À¯Çü ºÎ¹®Àº µð¹ÙÀ̽º Ä«Å×°í¸®°¡ 2024³â¿¡ °¡Àå Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÌ·¯ÇÑ ÀåÄ¡´Â ¸¸¼º Áúȯ °ü¸® ¹× ¿¹¹æ ÀÇ·á¿¡ ÇʼöÀûÀÌ¸ç µ¥ÀÌÅ͸¦ ºÐ¼®Çϰí ÀáÀçÀûÀÎ °Ç° ¹®Á¦¿¡ ´ëÇÑ Á¶±â °æ°í¸¦ Á¦°øÇÏ´Â ÅëÇÕ AI ¾Ë°í¸®ÁòÀ» ÅëÇØ ÀÇ·á Á¦°ø¾÷ü¿¡°Ô Àû½Ã¿¡ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
AI Áö¿ø ¿ø°Ý ¸ð´ÏÅ͸µ ÀåÄ¡´Â ½É¹Ú¼ö, Ç÷¾Ð, Ç÷Áß »ê¼Ò Æ÷ȵµ(SpO2), ½ÉÀüµµ(ECG)¿Í °°Àº »ýü ½ÅÈ£ÀÇ Áö¼ÓÀûÀÎ ÃßÀû°ú °°Àº °í±Þ ±â´ÉÀ» °®Ãß°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ¸¹Àº Àåºñ´Â Ŭ¶ó¿ìµå Ç÷§Æû ¹× °Ç° °ü¸® Á¦°ø¾÷ü¿¡°Ô Á÷Á¢ ¹«¼± µ¥ÀÌÅÍ Àü¼ÛÀ» Á¦°øÇÏ¿© Àû½Ã¿¡ ÀÓ»óÀû °³ÀÔÀ» º¸ÀåÇÕ´Ï´Ù.
ÀÌ Àåºñ´Â ºÎÁ¤¸Æ°ú ½ÉºÎÀü°ú °°Àº ½ÉÇ÷°ü°è ¸ð´ÏÅ͸µ, Áö¼ÓÀûÀÎ Æ÷µµ´ç ¸ð´ÏÅ͸µÀ» ÅëÇÑ ´ç´¢º´ °ü¸®, COPD¿Í °°Àº Áúº´¿¡¼ È£Èí±â ½Ã½ºÅÛÀÇ °Ç° ÃßÀû, ¼ö¼ú ÈÄ °ü¸®, º´¿ø¿¡¼ÀÇ ÀçÅà ÇÁ·Î±×·¥, ³«»ó °¨Áö ¹× À§Çè Æò°¡¸¦ À§ÇÑ ³ëÀÎ ¸ð´ÏÅ͸µ µîÀÇ ÁÖ¿ä ¿ëµµ¸¦ ã½À´Ï´Ù.
ÀÌ ºÐ¾ß¿¡¼´Â ¿©·¯ ¼¼°è ±â¾÷µéÀÌ Çõ½ÅÀûÀÎ Á¦Ç°À» Ãâ½ÃÇß½À´Ï´Ù. AppleÀÇ Watch Series 9´Â ECG, SpO2 ¸ð´ÏÅ͸µ, ºÎÁ¤¸Æ °æº¸ µîÀÇ ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. iRhythmÀÇ Zio Patch´Â ºÎÁ¤¸Æ °ËÃâÀ» À§ÇÑ AI¸¦ °®Ãá Àå±â ECG ¸ð´ÏÅ͸µÀ» Á¦°øÇÕ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ¸¸ÇÑ Á¦Ç°À¸·Î´Â MedtronicÀÇ LINQ II(TM) »ðÀÔÇü ½ÉÀå ¸ð´ÏÅͰ¡ ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ Áøº¸´Â AI¸¦ Ȱ¿ëÇÑ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ ¿äÁ¡À¸·Î ½º¸¶Æ® ÀÇ·á±â±â¿¡ ´ëÇÑ ÀÇÁ¸ÀÌ ³ô¾ÆÁö°í ÀÖÀ½À» ºÎ°¢Çϰí ÀÖÀ¸¸ç, ÀÌ ±â±â Ä«Å×°í¸®°¡ ÇâÈÄ ¼ö³â°£ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©ÇÒ °ÍÀÔ´Ï´Ù.
ÀÌ·¯ÇÑ »ó½Â¼¼´Â 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀå ÀüüÀÇ È®´ë¿¡ Å©°Ô ±â¿©ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ºÏ¹Ì´Â ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀå Àüü¸¦ Áö¹èÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ºÏ¹Ì´Â 2025³âºÎÅÍ 2032³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº ¾Ï µî ¸¸¼º ÁúȯÀÇ ºÎ´ã Áõ°¡, °ß°íÇÑ Çコ Äɾî ÀÎÇÁ¶ó, µðÁöÅÐ Çコ ±â¼úÀÇ ³ôÀº ä¿ë·ü, Á¤ºÎÀÇ Áö¿ø Á¤Ã¥ µîÀÔ´Ï´Ù. ÀÌ Áö¿ªÀº ¶ÇÇÑ µðÁöÅÐ °Ç°¿¡ ´ëÇÑ ´ë±Ô¸ð ÅõÀÚ¿Í ¿þ¾î·¯ºí ÀÇ·á±â±â ¹× Ä¿³ØÆ¼µå ÀÇ·á±â±âÀÇ º¸±ÞÀ¸·Î ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù.
¹Ì±¹ ±¹¸³¾Ï ¿¬±¸¼ÒÀÇ µ¥ÀÌÅÍ(2024³â)¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â 2024³â¿¡ 200¸¸¸íÀÌ »õ·Ó°Ô ¾ÏÀ¸·Î Áø´ÜµÈ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Àü¸³¼±¾Ï, Æó¾Ï, ´ëÀå¾ÏÀÌ ³²¼ºÀÇ ¾Ï Áø´Ü ÀüüÀÇ ¾à 48%¸¦ Â÷ÁöÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ¿©¼ºÀÇ °æ¿ì °¡Àå ÀÌȯÀ²ÀÌ ³ôÀº ¾ÏÀº À¯¹æ¾Ï, Æó¾Ï, ´ëÀå¾ÏÀ¸·Î ½Å±Ô ¾Ï Áø´Ü ÀüüÀÇ ¾à 51%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Global Cancer ObservatoryÀÇ µ¥ÀÌÅÍ(2024³â)¿¡ µû¸£¸é, 2022³â¿¡´Â ¹Ì±¹ÀÌ Àü¾Ï ȯÀÚÀÇ 89.1%¸¦, ij³ª´Ù°¡ 10.9%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
¹Ì±¹°ú ij³ª´ÙÀÇ ¾Ï ȯÀÚ ¼ö°¡ Áõ°¡Çϸé Áö¼ÓÀûÀÎ ÀçÅà °ü¸® ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ¹Ì±¹ Áúº´ ¿¹¹æ °ü¸® ¼¾ÅÍ(CDC, 2024³â)¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â ¸Å³â Æò±Õ 80¸¸ 5,000¸íÀÌ ½ÉÀå ¹ßÀÛÀ» ¹ßº´Çϰí ÀÖ½À´Ï´Ù.
ij³ª´Ù ½ÉÀåÇ÷°üÇÐȸ(2022³â)¿¡ µû¸£¸é, 2022³â¿¡´Â Àα¸ÀÇ 2.5%°¡ ½ÉÀ庴À» ¾Î°í ÀÖÀ¸¸ç, 65¼¼¸¦ Áö³ª¸é Å©°Ô Áõ°¡Çϰí, 75¼¼¸¦ Áö³ª¸é 13%¿¡ ´ÞÇÑ´Ù°í º¸°íµÇ°í ÀÖ½À´Ï´Ù.
½ÉÀå°ú °ü·ÃµÈ Áúº´ ¹× °ü·Ã À§Çè ÀÎÀÚÀÇ ºÎ´ã Áõ°¡·Î Áö¼ÓÀûÀ̰í È¿À²ÀûÀÎ ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ ¿äÀÎÀ» Á¾ÇÕÇÏ¸é ºÏ¹Ì´Â ½ÃÀå ¼ºÀåÀ» ¸Å¿ì Á¶ÀåÇϴ ȯ°æÀÌ µÇ¾î 2025³âºÎÅÍ 2032³â±îÁö ¿¹Ãø±â°£À» ÅëÇØ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ½ÃÀå AIÀÇ ÁÖ¿ä Áö¿ªÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀå¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷Àº Medtronic, iRhythm Inc., Koninklijke Philips NV, Siemens Healthineers, GE HealthCare, Apple Inc., alivecor Inc., Biofourmis, Optum, Inc., Headspace Health Medical, Implicity, Stryker, Biobeat µîÀÌ ÀÖ½À´Ï´Ù.
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ½ÃÀå AIÀÇ ÃÖ±Ù °³¹ß Ȱµ¿ :
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀå Á¶»ç º¸°í¼ÀÇ ÁÖ¿ä ¿äÁ¡
ÀÌ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ AI ½ÃÀå Á¶»ç º¸°í¼¿¡¼ ÀÌÀÍÀ» ¾òÀ» ¼ö ÀÖ´Â ´ë»óÀÚ
Artificial Intelligence (AI) in Remote Patient Monitoring Market by Product Type (Devices, Software, and Services), Application (Cancer, Cardiovascular Disorder, Lifestyle Disorders, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, and Homecare Setting), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a substantial CAGR forecast till 2032 owing to the increasing prevalence of chronic disease and growing product developmental activities worldwide.
The Artificial Intelligence (AI) in remote patient monitoring market was valued at USD 1,926.51 million in 2024, growing at a CAGR of 27.13% during the forecast period from 2025 to 2032 to reach USD 13,126.80 million by 2032. The Artificial Intelligence (AI) in remote patient monitoring (RPM) market is experiencing robust growth, fueled by the rising cases of chronic conditions such as cancer, cardiovascular diseases, and lifestyle-related disorders. This growth is further supported by a surge in product development initiatives, increasing global investments in digital health infrastructure, and a growing emphasis on proactive, data-driven healthcare. These factors are expected to drive significant expansion of the AI-powered remote patient monitoring (RPM) market during the forecast period from 2025 to 2032.
Artificial Intelligence (AI) in Remote Patient Monitoring Market Dynamics:
According to data provided by the International Agency for Research on Cancer (IARC) in 2024, stated that 20 million new cancer cases were reported in 2022 globally. As per the same source, lung cancer accounted for 2.5 million cases globally, of all the reported cancer cases, making it the most common cancer. Similarly, breast cancer accounted for 2.3 million cases, colon cancer for 1.9 million cases, and stomach cancer for 0.97 million cases globally.
The Global Cancer Observatory (2024), estimated that the new cases of cancer globally were expected to reach from 20 million in 2022 to 24.1 million by 2030. It stated that Asia accounted for 9,826,539 cancer cases, Europe accounted for 4,471,422 cancer cases, Latin America and the Caribbean (LAC) accounted for 1,551,060 cancer cases, and Africa accounted for 1,185,216 cancer cases.
The rising global cancer burden is accelerating demand for AI-powered remote patient monitoring to enable continuous, personalized care. AI-powered remote patient monitoring enhances early intervention, treatment tracking, and long-term survival support in clinical settings.
According to data from the International Diabetes Federation (2022), 537 million adults aged 20-79 were living with diabetes, equating to about 1 in 10 individuals. This number is expected to increase to 643 million by 2030 and reach 783 million by 2045. Notably, over 75% of adults with diabetes reside in low- and middle-income countries. Additionally, 541 million adults have impaired glucose tolerance (IGT), putting them at elevated risk for developing type 2 diabetes.
Hence, rising cases of diabetes and impaired glucose tolerance are driving demand for Artificial Intelligence (AI) in remote patient monitoring, as continuous tracking and early intervention are essential for effective disease management. AI-enabled RPM devices help clinicians monitor glucose levels, detect complications early, and personalize treatment plans.
Additionally, ongoing product development by key market players is significantly driving the growth of the AI-powered remote patient monitoring (RPM) market. For instance, in May 2024, DentalMonitoring(R) received De Novo approval from the U.S. Food and Drug Administration (FDA) for its innovative DentalMonitoring solution. This AI-driven remote patient monitoring software is specifically designed to support healthcare professionals in remotely tracking dental and orthodontic treatments, oral health conditions, and overall treatment progress. By enabling continuous, real-time monitoring outside of traditional clinical settings, the solution not only enhances patient care and compliance but also contributes to more efficient, personalized treatment pathways.
Nevertheless, the interplay of high instances of chronic conditions including cancer, cardiovascular diseases, and lifestyle-related disorders is expected to propel the market significantly during the forecast period from 2025 to 2032, with continuous surge in product development initiatives, increasing global investments in digital health infrastructure, and a growing emphasis on proactive, data-driven healthcare.
Despite its strong growth potential, Artificial Intelligence (AI) in remote patient monitoring market faces a few major challenges. Challenges such as data privacy and security concerns, Stringent regulations, and complexities in Artificial Intelligence (AI) integration could slow down its growth in the coming years.
Artificial Intelligence (AI) in Remote Patient Monitoring Market Segment Analysis:
Artificial Intelligence (AI) in Remote Patient Monitoring Market by Product Type (Devices, Software, and Services), Application (Cancer, Cardiovascular Disorder, Lifestyle Disorders, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, and Homecare Setting), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the Artificial Intelligence (AI) in remote patient monitoring market, the devices category is projected to hold the largest revenue share in 2024. This dominance is primarily driven by the widespread adoption of wearable and connected health devices integrated with artificial intelligence technology that enable continuous, real-time monitoring of patients outside traditional clinical settings.
These devices are essential in chronic disease management and preventive care, offering healthcare providers timely insights through integrated AI algorithms that analyze data and provide early warnings of potential health issues.
AI-enabled remote monitoring devices come equipped with advanced features such as continuous tracking of vital signs like heart rate, blood pressure, blood oxygen saturation (SpO2), and electrocardiograms (ECG).
Many devices also offer wireless data transmission to cloud platforms or directly to healthcare providers, ensuring timely clinical intervention. Additional functionalities include patient engagement tools, such as personalized health feedback and medication reminders, and seamless integration with electronic health record (EHR) systems and telehealth platforms, enhancing workflow efficiency.
These devices find key applications in cardiovascular monitoring (e.g., for arrhythmias and heart failure), diabetes management through continuous glucose monitoring, respiratory health tracking in conditions like COPD, post-operative care, hospital-at-home programs, and elderly monitoring for fall detection and risk assessment.
Several global companies launched innovative products in this space. Apple's Watch Series 9 offers features like ECG, SpO2 monitoring, and irregular heart rhythm alerts. iRhythm's Zio Patch provides long-term ECG monitoring powered by AI for arrhythmia detection. Other notable products include Medtronic's LINQ II(TM) insertable cardiac monitor, which provides long-term detection of abnormal heart rhythms.
These advancements highlight the increasing reliance on smart medical devices as a cornerstone of AI-powered remote patient monitoring, making the devices category a major contributor to market growth in the coming years.
This upward trend is expected to significantly contribute to the overall expansion of the Artificial Intelligence (AI) in remote patient monitoring market during the forecast period 2025 to 2032.
North America is expected to dominate the overall Artificial Intelligence (AI) in Remote Patient Monitoring market:
North America is anticipated to dominate the Artificial Intelligence (AI) in remote patient monitoring market during the forecast period 2025 to 2032. The growth of the market in the region is mainly attributed to several factors, including the rising burden of chronic diseases such as cancer, strong healthcare infrastructure, high adoption of digital health technologies, and supportive government policies. The region also benefits from major investments in digital health and the widespread use of wearable and connected medical devices.
As per the data from the National Cancer Institute (2024), it was estimated that 2 million new cases of cancer were diagnosed in the US in 2024. Furthermore, it was estimated that prostate, lung, and colorectal cancers are expected to represent approximately 48% of all cancer diagnoses in men. For women, the most prevalent cancers are breast, lung, and colorectal, which are expected to account for about 51% of all new cancer diagnoses.
According to Global Cancer Observatory's data (2024), in 2022, the US represented 89.1% of all cancer cases and Canada represented 10.9% of all cancer cases in the region.
The growing number of cancer cases in the U.S. and Canada is driving the need for continuous, at-home care solutions. This is boosting demand for Artificial Intelligence (AI) in Remote Patient Monitoring, as it helps manage treatment, monitor symptoms, and improve patient outcomes more efficiently outside hospital settings.
Further, the Centers for Disease Control and Prevention (CDC, 2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, According to an article published by the Centers for Disease Control and Prevention (CDC) in May 2024, approximately 6.2 million adults were suffering from heart failure in the United States in 2022.
According to the Canadian Cardiovascular Society (2022), it was reported that in 2022, 2.5% of the population had heart disease, which increased significantly after the age of 65, reaching up to 13% after the age of 75. It was also estimated by the same source that in 2040, Canada will have an estimated 1.5 million people over 65 years with heart disease.
The increasing burden of heart-related conditions and their associated risk factors is driving the need for continuous and efficient monitoring solutions. AI-powered remote patient monitoring supports early detection, real-time management, and personalized care for cardiovascular patients, helping to reduce complications and improve outcomes, especially in aging populations.
Collectively, these factors create a highly conducive environment for market growth, positioning North America as the leading region in the Artificial Intelligence (AI) in remote patient monitoring market throughout the forecast period from 2025 to 2032.
Artificial Intelligence (AI) in Remote Patient Monitoring Market key players:
Some of the key market players operating in the Artificial Intelligence (AI) in remote patient monitoring market include Medtronic, iRhythm Inc., Koninklijke Philips N.V., Siemens Healthineers, GE HealthCare, Apple Inc., alivecor Inc., Biofourmis, Optum, Inc., Headspace Health, Withings, NeuroRPM Inc., Caretaker Medical, Implicity, Stryker, Biobeat and others.
Recent Developmental Activities in the Artificial Intelligence (AI) in Remote Patient Monitoring Market:
Key Takeaways from the Artificial Intelligence (AI) in Remote Patient Monitoring Market Report Study
Target audience who can be benefited from this Artificial Intelligence (AI) in Remote Patient Monitoring Market Report Study
Frequently Asked Questions for the Artificial Intelligence (AI) in Remote Patient Monitoring Market: